<DOC>
	<DOCNO>NCT02880865</DOCNO>
	<brief_summary>This study aim provide evidence co-administration measles-mumps-rubella vaccine ( MMR ) live attenuate SA 14-14-2 Japanese encephalitis vaccine ( CD-JEV ) adversely affect immunogenicity safety .</brief_summary>
	<brief_title>Immunogenicity Safety Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella Vaccine</brief_title>
	<detailed_description>When incorporate new vaccine Expanded Programme Immunization ( EPI ) , important provide evidence introduce concurrently routine pediatric vaccine without significantly impair immune response vaccine maximize coverage minimize cost . This non-inferiority study aim compare CD-JEV MMR responses population child country MMR introduction ongoing plan . This information help ministries health evaluate addition CD-JEV routine EPI .</detailed_description>
	<mesh_term>Encephalitis</mesh_term>
	<mesh_term>Measles</mesh_term>
	<mesh_term>Rubella</mesh_term>
	<mesh_term>Encephalitis , Japanese</mesh_term>
	<mesh_term>Mumps</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Age 9 month &lt; 10 month time enrollment . Residence study area . At least one parent guardian willing provide write informed consent . Generally healthy free obvious health problem establish medical history , physical examination , clinical judgment . A parent guardian willing attend plan study visit allow home visit phone contact , require protocol . Previous receipt measlesmumpsrubella contain vaccine . Previous receipt Japanese encephalitis vaccine . History measles , mumps , rubella , Japanese encephalitis infection . Administration vaccine within 28 day prior administration study vaccine plan vaccination vaccine catchup dose routine EPI vaccine oral polio vaccine 28 day study vaccination . History allergic disease know hypersensitivity component study vaccine and/or follow administration vaccine include local program immunization . Use investigational nonregistered drug within 90 day prior administration study vaccine plan administration study period . Administration immunoglobulins and/or blood product within 90 day prior administration study vaccine plan administration study period . Chronic administration ( defined &gt; 7 day ) immunosuppressing immunemodifying agent within 14 day vaccination ( include systemic corticosteroid equivalent prednisone ≥0.5 mg/kg/day ; topical inhale steroid allow ) . Primary acquire immunodeficiency , include HIV infection , family history congenital hereditary immunodeficiency report parent . Acute chronic , clinically significant pulmonary , cardiovascular , hepatic , renal functional abnormality , determine medical history physical examination , might interfere study objective . Severely malnourished infant measure World Health Organization weightforheight table ( Zscore &lt; 3 ) . Any condition criterion , opinion study physician , might compromise wellbeing participant , compliance study procedure , interpretation outcome study . Acute illness time enrollment define presence moderate severe illness fever ( axillary temperature ≥38.0°C ) without fever ( severity determine discretion study physician ) . Acute illness temporary exclusion . Vaccination postpone least 7 day recovery . A visit reassessment may schedule 7 day temporary exclusion illness resolve . Eligibility study participation must reassess next visit .</criteria>
	<gender>All</gender>
	<minimum_age>9 Months</minimum_age>
	<maximum_age>9 Months</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>vaccine</keyword>
</DOC>